Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.25
Bid: 40.00
Ask: 40.50
Change: 0.25 (0.63%)
Spread: 0.50 (1.25%)
Open: 40.00
High: 40.50
Low: 39.75
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman Research: De-risking Moderna's partnership

8 May 2017 13:21

RNS Number : 4860E
Avacta Group PLC
08 May 2017
 

Hardman Research: De-risking of the partnership with Moderna

De-risking of the partnership with Moderna: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. Moderna was the first to enter into an agreement with Avacta to use the Affimer technology, in tandem with Moderna's mRNA drug delivery platform. Moderna has just disclosed Phase I trial data for its mRNA technology which is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRNA

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/08.05.17-de-risking-of-the-partnership-with-moderna.pdf

To contact us:

Hardman & Co

11/12 Tokenhouse Yard 

London

EC2R 7AS

Contacts:

Dr Martin Hall

mh@hardmanandco.com

Dr Dorothea Hill

dmh@hardmanandco.com

Dr Gregoire Pave

gp@hardmanabdco.com

Telephone: +44 20 7929 3399

Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABDGDURBGBGRI
Date   Source Headline
5th Oct 20117:00 amRNSSouth East Asian Alliance agreed with Pall
19th Sep 20117:00 amRNSNotice of Preliminary Results
9th Aug 20117:00 amRNSPre-close Trading Update
6th Jul 20117:00 amRNSChange of Registered Office
10th Jun 201112:50 pmRNSDirector/PDMR Shareholding
31st May 20117:00 amRNSAvacta secures second Optim sale in US
18th Apr 20117:00 amRNSInterim Results
12th Apr 201112:42 pmRNSIssue of Equity
29th Mar 20117:00 amRNSExclusive distribution agreement with DKSH Japan
28th Mar 20117:00 amRNSAdditional Listing
22nd Mar 201110:11 amRNSAdditional Listing
17th Mar 20117:00 amRNSDirectorate Change
4th Mar 20117:00 amRNSTrading Statement
23rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSRe Agreement
3rd Feb 20117:00 amRNSIssue of Equity
27th Jan 20114:55 pmRNSHolding(s) in Company
27th Jan 20117:00 amRNSDirector/PDMR Shareholding
26th Jan 20117:00 amRNSIssue of Equity
25th Jan 201111:57 amRNSHolding(s) in Company
21st Jan 20113:47 pmRNSAGM Result and Placing
12th Jan 20117:00 amPRNPlacing, Issue of Equity and related party transaction
5th Jan 201111:59 amPRNExercise of Warrants
4th Jan 20116:28 pmPRNHolding(s) in Company
4th Jan 20117:00 amRNSProduct Sale
31st Dec 20109:57 amPRNHolding(s) in Company
30th Dec 20102:36 pmPRNHolding(s) in Company
25th Nov 20107:00 amRNSProduct Launch
15th Nov 20107:00 amPRNGrant of Options to Directors
3rd Nov 20107:00 amRNSFinal Results
27th Oct 20107:00 amRNSProduct Sale
27th Oct 20107:00 amRNSProduct Sale
26th Oct 20107:00 amPRNIssue of Equity
14th Oct 20107:00 amRNSRe Agreement
20th Sep 20107:00 amPRNLicensing Agreement
7th Sep 20105:08 pmPRNHolding(s) in Company
6th Sep 20107:00 amPRNDistribution Agreement
6th Aug 20109:55 amPRNDirector/PDMR Shareholding
29th Jul 20107:00 amPRNIssue of Equity
6th Jul 20107:00 amPRNIssue of Equity
1st Jun 20107:00 amPRNChange of Adviser
30th Apr 20107:00 amPRNHalf-yearly Report
8th Mar 20107:00 amRNSNotice of Results and Trading Update
3rd Mar 20107:00 amRNSAcquisition
22nd Feb 20102:42 pmRNSDirector/PDMR Shareholding
25th Jan 20107:00 amRNSResult of AGM
21st Dec 200910:35 amRNSIssue of Equity
26th Nov 20097:03 amRNSPreliminary Results
26th Nov 20097:00 amRNSIssue of Equity
4th Nov 20097:00 amPRNNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.